Thus, as demonstrated by Zheng et al. (2014), berberine (BBR) activates the p38α MAPK signaling pathway, upregulates FOXO3 and p53, and inhibits the proliferation of non-small cell lung cancer (NSCLC) cells while inducing cell cycle arrest (Zheng et al., 2014). Here, TP53 is linked to non-small cell lung carcinoma.